GlassScriptPhysician profile
Haley R Feiler
NPI 1396317608
$3,906.07
in general payments reported to CMS, 2019-2025
30 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $540 · 2022: $2,888 · 2023: $343 · 2024: $15.13 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $478.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $478.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $664.85 | 2021-2023 | Valtoco |
| Abbvie INC. | $416.32 | 2021-2023 | |
| Alexion Pharmaceuticals, INC. | $295.71 | 2022-2023 | Ultomiris |
| Teva Pharmaceuticals USA, INC. | $276.55 | 2021-2022 | |
| Sk Life Science, INC. | $266.47 | 2021-2023 | |
| Biogen, INC. | $182.40 | 2021-2022 | |
| Amgen INC. | $178.43 | 2022-2023 | Aimovig |
| Celgene Corporation | $177.19 | 2022-2023 | Zeposia |
| Mdd US Operations, LLC | $159.27 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $148.00 | 2021-2022 | |
| Lundbeck LLC | $146.58 | 2022-2023 | Vyepti |
| Eisai INC. | $142.87 | 2022 | |
| Lilly USA, LLC | $118.71 | 2021-2023 | Emgality, Reyvow |
| Avanir Pharmaceuticals, INC. | $99.24 | 2022 | |
| Kyowa Kirin, INC. | $76.51 | 2022-2023 | Nourianz |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $73.98 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $69.66 | 2022 | |
| Amneal Pharmaceuticals LLC | $65.05 | 2022-2023 | Rytary |
| Supernus Pharmaceuticals, INC. | $55.75 | 2021-2023 | |
| Ucb, INC. | $45.07 | 2021 | |
| Impel Pharmaceuticals INC. | $42.28 | 2023 | Trudhesa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $38.22 | 2022 | |
| Genzyme Corporation | $31.80 | 2022 | |
| Collegium Pharmaceutical, INC. | $29.49 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $21.28 | 2023 | Nuedexta |
| Emd Serono, INC. | $20.58 | 2022 | |
| Janssen Pharmaceuticals, INC | $17.01 | 2022 | |
| Novo Nordisk INC | $16.19 | 2022 | |
| Csl Behring | $15.48 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $15.13 | 2024 | Dysport |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haley Feiler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.